Антон Наумов - Остеопороз
Осложнения фармакотерапии. Неблагоприятные побочные реакции лекарственных средств. Том 1 / Под ред. Д.В. Рейхарта. М.: Литтерра, 2007. 256 с. (серия «Осложнения фармакотерапии»).
Abrahamsen B. More on reports of esophageal cancer with oral bisphosphonate use. N Engl J Med. Apr 23, 2009. 360(17): 1789.
Abrahamsen B., Eiken P., Brixen K. Atrial fibrillation in fracture patients treated with oral bisphosphonates // J. Internal Medicine. 2009. Vol. 265. Р. 581–592.
Advisory Task Force on Bisphosphonaterelated osteonecrosis of the Jaws // American Association of oral and maxillofacial surgeons. American Association of oral and maxillofacial surgeons position paper on bisphosphonate-related osteonecrosis of the jaws // J. Oral Maxillofac Surg. 2007.Vol. 65. Р. 369–376.
Anderson P.H., O’Loughlin P.D., May B.K., Morris H.A. Modulation of CYP27B1 and CYP24 mRNA expression in bone is independent of circulating 1,25(OH)2D3 levels. Bone 2005, 36, 654–662.
Baroutsou B., Babiolakis D., Stamatiadou A. et al. Patient compliance and preference of alendronate once weekly administration in comparison with daily regimens for osteoporotic postmenopausal women // Ann. Rheum. Dis. 2004. V. 63 (Suppl. 1). P. 455 (SATO240).
Bhandari S.K., Pashayan S., Liu I.L., Rasgon S.A., Kujubu D.A., Tom T.Y., Sim J.J. (2011) 25-Hydroxyvitamin D levels and hypertension rates. J Clin Hypertens (Greenwich) 13: 170–177.
Black D.M., Delmas P.D., Eastell R., Reid I.R., Boonen S., Cauley J.A., Cosman F., Lakatos P., Leung P.C. et.al. Once-Yearly Zoledronic acid for treatment of postmenopausal osteoporosis // New England J. Medicine. 2007. Vol. 356. Р. 1809–1822.
Black D.M., Schwartz A.V., Ensrud K.E., Cauley J.A., Levis S., Quandt S.A., Satterfield S., Wallace R.B., Bauer D.C., Palermo L., Wehren L.E., Lombardi A., Santora A.C., Cummings S.R., FLEX Research Group. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA. 2006 Dec 27. 296(24): 2927–38.
Bolland M.J., Avenell A., Baron J.A., Grey A., MacLennan G.S., Gamble G.D., Reid I.R. (2010) Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: metaanalysis. BMJ. 341: c3691.
Bolland M.J., Barber P.A., Doughty R.N., Mason B., Horne A., Ames R., Gamble G.D., Grey A., Reid I.R. (2008) Vascular events in healthy older women receiving calcium supplementation: randomized controlled trial. BMJ. 336: 262–266.
Burgaz A., Orsini N., Larsson S.C., Wolk A. (2011) Blood 25-hydroxyvitamin D concentration and hypertension: a metaanalysis. J Hypertens 29: 636–645.
Burr D.B., Diab T., Koivunemi A., Koivunemi M., Allen M.R. Effects of 1 to 3 years’ treatment with alendronate on mechanical properties of the femoral shaft in a canine model: implications for subtrochanteric femoral fracture risk. J Orthop Res. 2009. Oct. 27(10): 1288–92.
Chesnut C.H., Skag A., Christiansen C., Recker R., Stakkestad J.A., Hoiseth A., Felsenberg D., Huss H., Gibride J., Schimmer R.C., Delmas P.D. Effects of oral ibandronate administered daily or intermittenly on fracture risk in postmenopausal osteoporosis //J. Bone and Mineral Research. 2004. Vol. 19. Р. 1241–1249.
Cramer J., Amonkar M.M., Hebborn A. et al. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis // Curr. Med. Res. Opin. 2005. V. 21. P. 1453–1460.
Cross H.S., Kallay, E. Regulation of the colonic vitamin D system for prevention of tumor progression: an update. Future Oncol. 2009, 5, 493–507.
Cryer B., Miller P., Petruschke R.A., Chen E., Geba G.P., Papp A.E. Upper gastrointestinal tolerability of once weekly alendronate 70 mg with concomitant non-steroidal anti-inflammatory drug use. Aliment Pharmacol Ther. 2005. Mar 1. 21(5): 599–607.
Dobnig H., Pilz S., Scharnagl H., Renner W., Seelhorst U., Wellnitz B., Kinkeldei J., Boehm B.O., Weihrauch G., Maerz W. Independent association of low serum 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D levels with all-cause and cardiovascular mortality. Arch. Intern. Med. 2008, 168, 1340–1349.
Emkey R., Koltun W., Beusterien K. et al. Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO) // Curr Med Res Opin. 2005. 21(12): 1895–1903.
Felsenberg D., Hoffmeister B., Amling M., Seibel M.J., Fratzl P. Kiefemekrosen nach hoch dosierter bisphosphonattherapie // Dtsch Arzebl. 2006. Vol. 103. Р. 3078–3081.
Foley R.N., Collins A.J., Ishani A., Kalra P.A. (2008) Calciumphosphate levels and cardiovascular disease in communitydwelling adults: the Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J 156: 556–563;!!!Vestergaard P., Mollerup C.L., Frokjaer V.G., Christiansen P., Blichert-Toft M., Mosekilde L. (2003) Cardiovascular events before and after surgery for primary hyperparathyroidism. World J Surg 27: 216–222.
Giovannucci E., Liu Y., Hollis B.W., Rimm E.B. (2008) 25-Hydroxyvitamin D and risk of myocardial infarction in men: a prospective study. Arch Intern Med 168:1174–1180.
Graham D. What the gastroenterologist should know about the gastrointestinal safety profiles of bisphosphonates. Dig Dis Sci. 2002. 47(8): 1665–78.
Halkin H., Dushenat M., Silverman B. еt al. Brand versus generic alendronate: gastrointestinal effects measured by resource utilization. Ann Pharmacother. 2007. 41(1): 29–34.
http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021817s003lbl.pdf
http://www.biomedcentral.com/content/pdf/1471-2474-10-113.pdf
http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm150837.htm
http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm079352.htm
Ing-Lorenzini K., Desmeules J., Plachta O., Suva D., Dayer P., Peter R. Low-energy femoral fractures associated with the longterm use of bisphosphonates: a case series from a Swiss university hospital // Drug Saf. 2009. Vol. 32. Р. 775–785.
Jackson R.D., LaCroix A.Z., Gass M. et al. (2006) Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 354:669–683; Hsia J., Heiss G., Ren H. et al. (2007) Calcium/vitamin D supplementation and cardiovascular events. Circulation 115: 846–854.
Janja Zupan, Radko Komadina, Janja Marc. The relationship between osteoclastogenic and anti-osteoclastogenic pro-inflammatory cytokines differs in human osteoporotic and osteoarthritic bone tissues // J Biomed Sci. 2012; 19(1): 28. Published online 2012 March 1.
Jarvinen T.L.N., Sievanen H., Khan K.M., Heinonen А., Kannus Р. Shifting the focus in fracture prevention from osteoporosis to falls. BMJ. 2008. 336: 124–126.
Kendler D., Kung A.W., Fuleihan Gel H. et al. Patients with osteoporosis prefer once weekly to once daily dosing with alendronate // Maturitas. 2004. V. 48. P. 243–251.
Lampropoulos, C. E. et al. Osteoporosis – a risk factor for cardiovascular disease? // Nat. Rev. Rheumatol. advance online publication 14 August 2012.
Lawson M.A., Xia Z., Barnett B.L., Triffitt J.T., Phipps R.J., Dunford J.E., Locklin R.M., Ebetino F.H., Russell R.G. Differences between bisphosphonates in binding affinities for hydroxyapatite // J. Biomed Mater Res B Appl Biomater. 2009. Vol. 92B. Р. 149–155.
Leung S., Ashar B.H., Miller R.G. Bisphosphonate-associated scleritis: a case report and review // South Med. 2005. Vol. 98. Р. 733–735.
Lewis J.R., Calver J., Zhu K., Flicker L., Prince R.L. (2011) Calcium supplementation and the risks of atherosclerotic vascular disease in older women: results of a 5-year RCTand a 4,5-year follow-up. J Bone Miner Res 26: 35–41.
Lyles K.W., Colon-Emeric C.S., Magaziner J.S., Adachi J.D., Pieper C.F., Mautalen C., Hyldstrup L., Recknor C., Nordsletten L., Moore K.A. et. al. Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture // New England J. Medicine. 2007. Vol. 357. Р. 1799–1809.
MacLean C., NewbeОРy S., Maglione M., McMahon M., Ranganath V., Suttorp M., Mojica W., Timmer M., Alexander A., McNamara M., Desai S.B., Zhou A., Chen S., Carter J., Tringale C., Valentine D., Johnsen B., Grossman J. Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med. 2008. Feb 5.148(3): 197–213.
Mak A. Bisphosphonates and atrial fibrillation: Bayesian meta-analyses of randomized controlled trials and observational studies. BMC Musculoskeletal Disorders. 2009, 10: 113.
Martin Fortin, Moira Stewart, Marie-Eve Poitras, José Almirall, Heather Maddocks. Systematic Review of Prevalence Studies on Multimorbidity: Toward a More Uniform Methodology // Ann Fam Med March/April 2012 vol. 10 no. 2 142–151.
Mavrokokki T., Cheng A., Stein B., Goss A. Nature and frequency of bisphosphonateassociated osteonecrosis of the jaws in Australia // J. Oral Maxillofac Surg. 2007. Vol. 65. Р. 415–423.
Nancollas G.H., Tang R., Phipps R.J., Henneman Z., Gulde S., Wu W., Mangood A., Russell R.G., Ebetino F.H. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite // Bone. 2006. Vol. 38. Р. 617–627.
Oliver D., Connelly J.B., Victor C.R., Shaw F.E., Whitehead A., Genc Y. et al. Strategies to prevent falls and fractures in hospitals and care homes and effect of cognitive impairment: systematic review and meta-analyses. BMJ. 2007, 334: 82.
Pazians M., Blumentals W.A., Miller P.D. Lack of association between oral bisphosphonates and osteonecrosis using jaw surgery as a surrogate marker // Osteoporosis International. 2008. Vol. 19. Р. 773–779.
Peterlik M., Cross H.S. Vitamin D and calcium insufficiency-related chronic diseases: molecular and cellular pathophysiology // Eur. J. Clin. Nutr. 2009.
Pilz S., Dobnig H., Fischer J.E., Wellnitz B., Seelhorst U., Boehm B.O., Marz W. (2008) Low vitamin d levels predict stroke in patients referred to coronary angiography. Stroke 39:2611–2613.
Pilz S., Marz W., Wellnitz B., Seelhorst U., Fahrleitner-Pammer A., Dimai H.P., Boehm B.O., Dobnig H. (2008) Association of vitamin D deficiency with heart failure and sudden cardiac death in a large cross-sectional study of patients referred for coronary angiography. J Clin Endocrinol Metab 93: 3927–3935.
Pilz S., Tomaschitz A., Drechsler C., Dekker J.M., Marz W. Vitamin D deficiency and myocardial diseases. //Mol Nutr Food, 2010, Res 54:1103–1113.
Pilz S., Tomaschitz A., Ritz E., Pieber T.R. (2009) Vitamin D status and arterial hypertension: a systematic review. Nat Rev Cardiol 6: 621–630.
Pittas A.G., Lau J., Hu F.B., Dawson-Hughes B. (2007) The role of vitamin D and calcium in type 2 diabetes. A systematic review and meta-analysis. J Clin Endocrinol Metab 92: 2017–2029.
Recker R., Ensrud K., Diem S. et al. Normal bone histomorphometry and 3D microarchitecture after 10 years alendronate treatment of postmenopausal women // J. Bone Miner. Res. 2004; 19:45.
Recker О.Р., Delmas P.D., Halse J. et al. Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure. J Bone Miner Res. 2008 Jan; 23(1): 6–16.
Recker О.Р., Weinstein R.S., Chesnut C.H. 3rd, et al. Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: results from the BONE study. Osteoporos Int. 2004 Mar. 15(3): 231–7.
Reid I.R., Schooler B.A., Hannan S.F., Ibbertson H.K. (1986) The acute biochemical effects of four proprietary calcium preparations. Aust N Z J Med 16: 193–197.
Rodan G., Reszka A., Golub E., Rizzoli R. Bone safety of long-term bisphosphonate treatment // Curr. Med. Res. Opin. 2004; 20(8): 1291–1300.
Russell R.G., Watts N.B., Ebetino F.H., Rogers M.J. Mechanisms of actions of bisphosphonates: similarities and differences and their potential influence on clinical efficacy // Osteoporosis International. 2008. Vol. 19.Р. 733–759.
Schleithoff S.S., Zittermann A., Tenderich G., Berthold H.K., Stehle P., Koerfer R. (2006) Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. Am J Clin Nutr. 83: 754–759.
Shaheen N.J. More on reports of esophageal cancer with oral bisphosphonate use. N Engl J Med. Apr 23, 2009. 360(17): 1790–1791.
Simon J.A., Lewiecki E.M., Smith M.E. et al. Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, cross-over study // Clin. Ther. 2002. V. 24. P. 1871–1886.
Siris E.S., Oster M.W., Bilezikian J.P. More on reports of esophageal cancer with oral bisphosphonate use. N Engl J Med. Apr 23, 2009. 360(17): 1791.
Solomon D.H., Avorn J., Katz J.N., et al. Compliance with osteoporosis medications. Arch Intern Med. 2005. 165: 2414–2419.
Solomon D.H., Patrick A., Brookhart M.A. More on reports of esophageal cancer with oral bisphosphonate use. N Engl J Med. Apr 23, 2009. 360(17): 1789–1790.
Sook-Bin W., Hellstein J.W., Kalmar J.R. Systematic review: Bisphosphonates and osteonecrosis of the jaws // Ann Intern Med. 2006. Vol. 144. Р. 753–761.
Sorensen H.T., Christensen S., Mehnert F., Pedersen L., Chapurlat R.D., Cummings S.R., Baron J.A. Use of bisphosphonates among women and risk оf atrial fibrillation and flutter: population based case-control study // BMJ. 2008. Vol. 336. Р. 813–816.
Sugden J.A., Davies J.I., Witham M.D., Morris A.D., Struthers A.D. (2008) Vitamin D improves endothelial function in patients with type 2 diabetes mellitus and low vitamin D levels. Diabet Med 25:320–325.
Tishkoff D.X., Nibbelink K.A., Holmberg K.H., Dandu L., Simpson R.U. (2008) Functional vitamin D receptor (VDR) in the t-tubules of cardiac myocytes: VDR knockout cardiomyocyte contractility. Endocrinology. 149: 558–564.
Vаlean S., Petrescu M., Cаtinean A. et al. Pill esophagitis. Rom J Gastroenterol. 2005. 14(2): 159–63.
Wang T.J., Pencina M.J., Booth S.L., Jacques P.F., Ingelsson E., Lanier K., Benjamin E.J., D’Agostino R.B., Wolf M., Vasan R.S. (2008) Vitamin D deficiency and risk of cardiovascular disease. Circulation 117: 503–511;!!!Autier P., Gandini S. (2007) Vitamin D supplementation and total mortality: a meta-analysis of randomized controlled trials. Arch Intern Med 167: 1730–1737.
